Human genomic association studies: A primer for the infectious diseases specialist

Journal of Infectious Diseases

Volumn 195, Issue 12, 2007, Pages 1737-1744

  Motsinger, Alison A ^a   Haas, David W ^a   Hulgan, Todd ^a   Ritchie, Marylyn D ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5; EFAVIRENZ; INDINAVIR; INTERLEUKIN 10; NELFINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA;

CONTROLLED STUDY; GENETIC ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERSENSITIVITY REACTION; INFECTION; LABORATORY DIAGNOSIS; LIPOATROPHY; MATHEMATICAL COMPUTING; MEDICAL SPECIALIST; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; VALIDATION PROCESS;

COMMUNICABLE DISEASES; GENOME, HUMAN; GENOMICS; HAPLOTYPES; HIV INFECTIONS; HUMANS; LINKAGE (GENETICS); PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RESEARCH DESIGN;

EID: 34249907829     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/518247     Document Type: Review

References (114)

1. Biggar RJ, Ng J, Kim N, et al. Human leukocyte antigen concordance and the transmission risk via breast-feeding of human T cell lymphotropic virus type 1. J Infect Dis 2006; 193:277-82.
2. Brown EE, Fallin MD, Goedert JJ, et al. Host immunogenetics and control of human herpesvirus-8 infection. J Infect Dis 2006; 193:1054-62.
3. Dai CY, Chuang WL, Chang WY, et al. Tumor necrosis factor-α promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection. J Infect Dis 2006; 193:98-101.
4. Kimura T, Saito T, Yoshimura M, et al. Association of transforming growth factor-β 1 functional polymorphisms with natural clearance of hepatitis C virus. J Infect Dis 2006; 193:1371-4.
5. Lajoie J, Hargrove J, Zijenah LS, Humphrey JH, Ward BJ, Roger M. Genetic variants in nonclassical major histocompatibility complex class I human leukocyte antigen (HLA)-E and HLA-G molecules are associated with susceptibility to heterosexual acquisition of HIV-1. J Infect Dis 2006; 193:298-301.
6. Liu H, Carrington M, Wang C, et al. Repeat-region polymorphisms in the gene for the dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-related molecule: effects on HIV-1 susceptibility. J Infect Dis 2006; 193:698-702.
7. Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Poland GA. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine. J Infect Dis 2006; 193:655-63.
8. Puthothu B, Krueger M, Forster I, Heinzmann A. Association between severe respiratory syncytial virus infection and IL13/IL4 haplotypes. J Infect Dis 2006; 193:438-41.
9. Ramasawmy R, Cunha-Neto E, Fae KC, et al. BAT1, a putative anti-inflammatory gene, is associated with chronic Chagas cardiomyopathy. J Infect Dis 2006; 193:1394-9.
10. Shrestha S, Strathdee SA, Galai N, et al. Behavioral risk exposure and host genetics of susceptibility to HIV-1 infection. J Infect Dis 2006; 193:16-26.
11. Moore JH. The ubiquitous nature of epistasis in determining susceptibility to common human diseases. Hum Hered 2003; 56:73-82.
12. Sing C, Haviland M, Templeton A, Zerba K, Reilly S. Biological complexity and strategies for finding DNA variations responsible for inter-individual variation in risk of a common chronic disease, coronary artery disease. Ann Med 1992; 24:539-47.
13. Templeton A. Epistasis and complex traits. Oxford: Oxford University Press, 2000.
14. Moore JH, Williams SM. Traversing the conceptual divide between biological and statistical epistasis: systems biology and a more modern synthesis. Bioessays 2005; 27:637-46.
15. Risch NJ. Searching for genetic determinants in the new millennium. Nature 2000; 405:847-56.
16. Feingold E. Methods for linkage analysis of quantitative trait loci in humans. Theor Popul Biol 2001; 60:167-80.
17. Daly AK, Day CP. Candidate gene case-control association studies: advantages and potential pitfalls. Br J Clin Pharmacol 2001; 52:489-99.
18. Healy DG. Case-control studies in the genomic era: a clinician's guide. Lancet Neurol 2006; 5:701-7.
19. Cargill M, Altshuler D, Ireland J, et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 1999; 22:231-8.
20. Thomas PD, Campbell MJ, Kejariwal A, et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res 2003; 13:2129-41.
21. Thomas PD, Kejariwal A, Campbell MJ, et al. PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucleic Acids Res 2003; 31:334-41.
22. Reumers J, Schymkowitz J, Ferkinghoff-Borg J, Stricher F, Serrano L, Rousseau F. SNPeffect: a database mapping molecular phenotypic effects of human non-synonymous coding SNPs. Nucleic Acids Res 2005; 33:D527-32.
23. Reumers J, Maurer-Stroh S, Schymkowitz J, Rousseau F. SNPeffect v2.0: a new step in investigating the molecular phenotypic effects of human non-synonymous SNPs. Bioinformatics 2006; 22:2183-5.
24. Daly MJ, Rioux JD, Schaffner SF, Hudson TJ, Lander ES. High-resolution haplotype structure in the human genome. Nat Genet 2001; 29:229-32.
25. Jeffreys AJ, Ritchie A, Neumann R. High resolution analysis of haplotype diversity and meiotic crossover in the human TAP2 recombination hotspot. Hum Mol Genet 2000; 9:725-33.
26. Jeffreys AJ, Kauppi L, Neumann R. Intensely punctate meiotic recombination in the class II region of the major histocompatibility complex. Nat Genet 2001; 29:217-22.
27. Johnson GC, Esposito L, Barratt BJ, et al. Haplotype tagging for the identification of common disease genes. Nat Genet 2001; 29:233-7.
28. Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ, Donnelly P. A haplotype map of the human genome. Nature 2005; 437:1299-320.
29. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004; 74:106-20.
30. Halldorsson BV, Istrail S, De la Vega FM. Optimal selection of SNP markers for disease association studies. Hum Hered 2004; 58:190-202.
31. Avi-Itzhak HI, Su X, De la Vega FM. Selection of minimum subsets of single nucleotide polymorphisms to capture haplotype block diversity. Pac Symp Biocomput 2003; 466-77.
32. Motsinger AA, Ritchie MD, Dobrin SE. Clinical applications of whole-genome association studies: future applications at the bedside. Expert Rev Mol Diagn 2006; 6:551-65.
33. Ardlie KG, Kruglyak L, Seielstad M. Patterns of linkage disequilibrium in the human genome. Nat Rev Genet 2002; 3:299-309.
34. Pritchard JK, Przeworski M. Linkage disequilibrium in humans: models and data. Am J Hum Genet 2001; 69:1-14.
35. Salisbury BA, Pungliya M, Choi JY, Jiang R, Sun XJ, Stephens JC. SNP and haplotype variation in the human genome. Mutat Res 2003; 526:53-61.
36. Moore JH, Ritchie MD. STUDENTJAMA: the challenges of whole-genome approaches to common diseases. JAMA 2004; 291:1642-3.
37. Akey J, Jin L, Xiong M. Haplotypes vs single marker linkage disequilibrium tests: what do we gain? Eur J Hum Genet 2001; 9:291-300.
38. Xiong M, Akey J, Jin L. The haplotype linkage disequilibrium test for genome-wide screens: its power and study design. Pac Symp Biocomput 2000; 675-86.
39. Fallin D, Cohen A, Essioux L, et al. Genetic analysis of case/control data using estimated haplotype frequencies: application to APOE locus variation and Alzheimer's disease. Genome Res 2001; 11:143-51.
40. Zhang S, Pakstis AJ, Kidd KK, Zhao H. Comparisons of two methods for haplotype reconstruction and haplotype frequency estimation from population data. Am J Hum Genet 2001; 69:906-14.
41. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-5.
42. Liu K, Muse SV. PowerMarker: an integrated analysis environment for genetic marker analysis. Bioinformatics 2005; 21:2128-9.
43. Gibson G. Epistasis and pleiotropy as natural properties of transcriptional regulation. Theor Popul Biol 1996; 49:58-89.
44. Sing CF, Stengard JH, Kardia SL. Dynamic relationships between the genome and exposures to environments as causes of common human diseases. World Rev Nutr Diet 2004; 93:77-91.
45. Thornton-Wells TA, Moore JH, Haines JL. Genetics, statistics and human disease: analytical retooling for complexity. Trends Genet 2004; 20:640-7.
46. Wilke RA, Reif DM, Moore JH. Combinatorial pharmacogenetics. Nat Rev Drug Discov 2005; 4:911-8.
47. Bellman R. Adaptive control processes. Princeton: Princeton University Press, 1961.
48. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 1995; 48:1503-10.
49. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996; 49:1373-9.
50. Moore JH, Williams SM. New strategies for identifying gene-gene interactions in hypertension. Ann Med 2002; 34:88-95.
51. Moore JH. Computational analysis of gene-gene interactions using multifactor dimensionality reduction. Expert Rev Mol Diagn 2004; 4:795-803.
52. Hoh J, Wille A, Ott J. Trimming, weighting, and grouping SNPs in human case-control association studies. Genome Res 2001; 11:2115-9.
53. Nelson MR, Kardia SL, Ferrell RE, Sing CF. A combinatorial partitioning method to identify multilocus genotypic partitions that predict quantitative trait variation. Genome Res 2001; 11:458-70.
54. Ritchie MD, Hahn LW, Roodi N, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 2001; 69:138-47.
55. Millstein J, Conti DV, Gilliland FD, Gauderman WJ. A testing framework for identifying susceptibility genes in the presence of epistasis. Am J Hum Genet 2006; 78:15-27.
56. Motsinger AA, Dudek SM, Hahn LW, Ritchie MD. Comparison of neural network optimization approaches for studies of human genetics. Lect Notes Comput Sci 2006; 3907:103-4.
57. Ritchie MD, Coffey CS, Moore JH. Genetic programming neural networks: a bioinformatics tool for human genetics. Lect Notes Comput Sci 2004; 3102:438-48.
58. Van SK, McQueen MB, Herbert A, et al. Genomic screening and replication using the same data set in family-based association testing. Nat Genet 2005; 37:683-91.
59. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995; 57:289-300.
60. Thompson WD. Effect modification and the limits of biological inference from epidemiologic data. J Clin Epidemiol 1991; 44:221-32.
61. Freimer NB, Sabatti C. Guidelines for association studies in human molecular genetics. Hum Mol Genet 2005; 14:2481-3.
62. Colhoun HM, McKeigue PM, Davey SG. Problems of reporting genetic associations with complex outcomes. Lancet 2003; 361:865-72.
63. Reich DE, Lander ES. On the allelic spectrum of human disease. Trends Genet 2001; 17:502-10.
64. Weiss KM, Terwilliger JD. How many diseases does it take to map a gene with SNPs? Nat Genet 2000; 26:151-7.
65. Wright AF, Hastie ND. Complex genetic diseases: controversy over the Croesus code. Genome Biol 2001; 2:COMMENT2007. Epub 2001 Aug 1.
66. Cox DG, Kraft P. Quantification of the power of Hardy-Weinberg equilibrium testing to detect genotyping error. Hum Hered 2006; 61:10-4.
67. Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet 2005; 76:887-93.
68. Pritchard JK, Stephens M, Rosenberg NA, Donnelly P. Association mapping in structured populations. Am J Hum Genet 2000; 67:170-81.
69. Devlin B, Roeder K. Genomic control for association studies. Biometrics 1999; 55:997-1004.
70. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000; 155:945-59.
71. Kohane IS, Masys DR, Altman RB. The incidentalome: a threat to genomic medicine. JAMA 2006; 296:212-5.
72. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001; 29:306-9.
73. Ioannidis JP, Ntzani EE, Trikalinos TA. 'Racial' differences in genetic effects for complex diseases. Nat Genet 2004; 36:1312-8.
74. Cardon LR, Palmer LJ. Population stratification and spurious allelic association. Lancet 2003; 361:598-604.
75. Lewis CM. Genetic association studies: design, analysis and interpretation. Brief Bioinform 2002; 3:146-53.
76. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene: Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273:1856-62.
77. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722-5.
78. Stephens JC, Reich DE, Goldstein DB, et al. Dating the origin of the CCR5-Δ32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet 1998; 62:1507-15.
79. Galvani AP, Slatkin M. Evaluating plague and smallpox as historical selective pressures for the CCR5-Delta 32 HIV-resistance allele. Proc Natl Acad Sci USA 2003; 100:15276-9.
80. Kaslow RA, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996; 2:405-11.
81. Saah AJ, Hoover DR, Weng S, et al. Association of HLA profiles with early plasma viral load, CD4+ cell count and rate of progression to AIDS following acute HIV-1 infection: Multicenter AIDS Cohort Study. AIDS 1998; 12:2107-13.
82. MacDonald KS, Embree J, Njenga S, et al. Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type I transmission. J Infect Dis 1998; 177:551-6.
83. Carrington M, Nelson GW, Martin MP, et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999; 283:1748-52.
84. Tang J, Costello C, Keet IP, et al. HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 1999; 15:317-24.
85. Keet IP, Tang J, Klein MR, et al. Consistent associations of HLA class I and II and transporter gene products with progression of human immunodeficiency virus type 1 infection in homosexual men. J Infect Dis 1999; 180:299-309.
86. Gao X, Nelson GW, Karacki P, et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med 2001; 344:1668-75.
87. Tang J, Wilson CM, Meleth S, et al. Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents. AIDS 2002; 16:2275-84.
88. Liu C, Carrington M, Kaslow RA, et al. Association of polymorphisms in human leukocyte antigen class I and transporter associated with antigen processing genes with resistance to human immunodeficiency virus type 1 infection. J Infect Dis 2003; 187:1404-10.
89. Dorak MT, Tang J, Penman-Aguilar A, et al. Transmission of HIV-1 and HLA-B allele-sharing within serodiscordant heterosexual Zambian couples. Lancet 2004; 363:2137-9.
90. Martin MP, Dean M, Smith MW, et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998; 282:1907-11.
91. Michael NL, Louie LG, Rohrbaugh AL, et al. The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nat Med 1997; 3:1160-2.
92. An P, Martin MP, Nelson GW, et al. Influence of CCR5 promoter haplotypes on AIDS progression in African-Americans. AIDS 2000; 14:2117-22.
93. Tang J, Wilson CM, Schaen M, Myracle A, Douglas SD, Kaslow RA. CCR2 and CCR5 genotypes in HIV type 1-infected adolescents: limited contributions to variability in plasma HIV type 1 RNA concentration in the absence of antiretroviral therapy. AIDS Res Hum Retroviruses 2002; 18:403-12.
94. Tang J, Shelton B, Makhatadze NJ, et al. Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression. J Virol 2002; 76:662-72.
95. Faure S, Meyer L, Costagliola D, et al. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 2000; 287:2274-7.
96. An P, Nelson GW, Wang L, et al. Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc Natl Acad Sci USA 2002; 99:10002-7.
97. Gonzalez E, Rovin BH, Sen L, et al. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci USA 2002; 99:13795-800.
98. Modi WS, Goedert JJ, Strathdee S, et al. MCP-1-MCP-3-eotaxin gene cluster influences HIV-1 transmission. AIDS 2003; 17:2357-65.
99. Gonzalez E, Kulkarni H, Bolivar H, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005; 307:1434-40.
100. Winkler C, Modi W, Smith MW, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant: ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 1998; 279:389-93.
101. Shin HD, Winkler C, Stephens JC, et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci USA 2000; 97:14467-72.
102. Martin MP, Gao X, Lee JH, et al. Epistatic interaction between KIR3DSI and HLA-B delays the progression to AIDS. Nat Genet 2002; 31:429-34.
103. An P, Bleiber G, Duggal P, et al. APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol 2004; 78:11070-6.
104. Haas DW. Human genetic variability and HIV treatment response. Curr HIV/AIDS Rep 2006; 3:53-8.
105. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359:727-32.
106. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359:1121-2.
107. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391-400.
108. Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult AIDS Clinical Trials Group Study. J Infect Dis 2005; 192:1931-42.
109. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005; 15:1-5.
110. Lillibridge JH, Lee CA, Pithavala YK. The role of polymorphic CYP2C19 in the metabolism of nelfinavir mesylate [abstract 3035]. In: Programs and Abstracts of the XII annual meeting and exposition of the American Association of Pharmaceutical Scientists (San Francisco). Arlington, VA: American Association of Pharmaceutical Scientists, 1998.
111. Zucker SD, Qin X, Rouster SD, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA 2001; 98:12671-6.
112. O'Mara E, Randall D, Passarell J, Steinberg S, Grasela D, Cirincione B. Population pharmacodynamic assessment of atazanavir exposure, uridine diphosphate-glucuronosyl transferase (UGT) 1A1 genotype and safety in healthy subjects [abstract A-1253]. Available at: http://gateway.nlm.nih.gov/ MeetingAbstracts/102267268.html. Accessed 7 May 2007.
113. Maher B, Alfirevic A, Vilar FJ, Wilkins EG, Park BK, Pirmohamed M. TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS 2002; 16:2013-8.
114. Nolan D, Moore C, Castley A, et al. Tumour necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS 2003; 17:121-3.